Shah Ashok J, Jadidi Amir S, Miyazaki Shinsuke, Xhaet Olivier, Linton Nick, Scherr Daniel, Liu Xingpeng, Forclaz Andrei, Nault Isabelle, Rivard Lena, Derval Nicolas, Sacher Frederic, Bordachar Pierre, Ritter Philippe, Hocini Meleze, Jais Pierre, Haissaguerre Michel
Hôpital Cardiologique du Haut-Lévêque and the Université Bordeaux II, Bordeaux, France.
Discov Med. 2010 Sep;10(52):201-8.
Atrial fibrillation (AF) is the most common heart rhythm problem and a leading cause of morbidity and mortality. Serious complications associated with this disorder include cardioembolic stroke, heart failure, and death. The worldwide prevalence of AF is rapidly increasing owing to aging of the population. Abnormal impulse formation in the pulmonary veins is known to trigger paroxysmal AF and radiofrequency isolation of these veins is recommended in drug-refractory AF. Active pharmacological research is directed towards selectively targeting the culprit venous cells. Persistent AF is more likely to be an atrial disease. Intrinsic and extrinsic stressors are believed to cause electrostructural alterations in the atrial tissue leading to profibrillatory state. Further research will elucidate the role of stressors and help develop biomarkers to guide early management of AF. An ideal therapy for AF aims at prevention of onset and progression of AF and reduction of AF-related symptoms, hospitalization, stroke, and mortality.
心房颤动(AF)是最常见的心律失常问题,也是发病和死亡的主要原因。与这种疾病相关的严重并发症包括心源性栓塞性中风、心力衰竭和死亡。由于人口老龄化,全球范围内房颤的患病率正在迅速上升。已知肺静脉中异常的冲动形成会引发阵发性房颤,对于药物难治性房颤,建议对这些静脉进行射频隔离。积极的药理学研究旨在选择性地靶向罪魁祸首静脉细胞。持续性房颤更可能是一种心房疾病。内在和外在应激源被认为会导致心房组织发生电结构改变,从而导致促纤颤状态。进一步的研究将阐明应激源的作用,并有助于开发生物标志物以指导房颤的早期管理。理想的房颤治疗旨在预防房颤的发生和进展,并减轻与房颤相关的症状、住院率、中风和死亡率。